With Eylea rival in clinic, once-stealthy Kalaris finds public path via merger

A reverse merger will bring Samsara-backed Kalaris onto NASDAQ as it advances a long-acting VEGF inhibitor through the clinic that may have advantages over marketed therapies.

Kalaris Therapeutics Inc. is merging with AlloVir Inc. (NASDAQ:ALVR) several months after that company discontinued development of an antiviral T cell therapy that had reached Phase III testing...